Meldonium Olpha (Meldonium Dihydrate)

Meldonium blocks the enzyme γ‑butyrobetaine hydroxylase, which lowers the body’s production of carnitine. With less carnitine, heart muscle cells decrease fatty‑acid oxidation and increase glucose oxidation, a pathway that generates more ATP per unit of oxygen. This metabolic shift helps the heart work more efficiently during periods of limited oxygen supply.

The appropriate dose of Meldonium Olpha is determined by the prescribing clinician based on the patient’s medical condition, age, renal function and other individual factors. Dosage regimens can vary, and the prescriber will provide specific instructions that should be followed exactly as written.

Safety data for Meldonium during pregnancy and lactation are limited. Because potential risks cannot be ruled out, the drug should only be used if the prescriber judges that the potential benefit outweighs any possible harm to the fetus or infant. Consultation with a healthcare professional is essential before starting therapy.

To request Meldonium Olpha, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Meldonium’s primary alternative in the anti‑ischemic space is trimetazidine, which also shifts myocardial metabolism toward glucose utilization. Unlike trimetazidine, Meldonium reduces carnitine synthesis, potentially offering a different safety profile. Both agents aim to improve cardiac efficiency, but selection depends on individual patient characteristics, tolerability and physician preference.

Meldonium Olpha should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain stability.

Meldonium Olpha is administered orally. The tablets (or other oral dosage form) are taken with water, usually with or without food as directed by the prescriber. Patients should follow the exact dosing schedule provided by their healthcare professional and should not alter the regimen without medical advice.

Serious adverse reactions, although rare, include significant hypotension, cardiac arrhythmias, marked elevation of liver enzymes and severe allergic skin reactions such as rash or urticaria. If any of these symptoms develop, the patient should seek immediate medical attention and discuss discontinuation with the prescriber.

Meldonium Olpha is contraindicated in patients with known hypersensitivity to Meldonium or any of its excipients. Caution is also advised for individuals with severe renal or hepatic impairment, uncontrolled cardiac arrhythmias, and those taking medications that may cause dangerous additive cardiac effects. A healthcare professional should evaluate suitability before initiating therapy.